Recent data suggest that pSTAT5 is detectable in the cytoplasm of neoplastic cells in patients with AML, CML and SM, and that STAT5 acts as a pro-oncogenic driver in these myeloid neoplasms [28,29,30,58,59,60]. Here, STAT5A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.